Covid-19 vaccine update
Sign up for myFT Daily Digest and be the first to learn about the Covid-19 vaccine news.
After India’s export ban, manufacturing issues, and delays in new vaccine approvals derailed the plan, Covax has lowered its forecast for the provision of coronavirus vaccines to developing countries this year by approximately 25%.
The delivery of vaccines to low- and middle-income countries under the plan is increasing, and 1.1 billion doses of vaccine will be provided for the rest of this year. But Covax will not be able to achieve its goal of delivering 2 billion vaccines this year, for a total of 1.4 billion vaccines.
Soumya Swaminathan, the chief medical officer of the World Health Organization who supports Covax, said that if vaccines can be shared more equally, there are still about 10,000 people who die from Covid-19 every day. prevention”.
She said that by the end of September, there will be enough supplies to vaccinate medical staff and the elderly around the world and significantly reduce the mortality rate.
“I am very worried that some countries talk about boosters without a lot of evidence that vaccines fail to protect people from serious diseases,” she said.
For three main reasons, the forecast has been lowered. In March of this year, India blocked the world’s largest vaccine manufacturer Serum Institute from exporting the doses of Oxford/AstraZeneca and Novavax vaccines originally scheduled to be sent to developing countries. Covax is negotiating with the Indian government to lift the ban.
The second setback is production interruption, mainly due to the suspension of Johnson & Johnson and AstraZeneca vaccine production, including problems at the Emergent Biosolutions plant in the United States. The third delay is due to the fact that Novavax and Clover vaccines have not yet been approved.